ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

India's drugmakers squeezed as generics weaken, specialty drugs yet to take off

MUMBAI (NewsRise) -- As sales in key export markets dwindle, India's top drugmakers are under pressure to transform their product portfolio, a process that is proving painful for the companies as well as for investors.

Not only are profits from the mainstay generics business crumbling, the heavy capital investment required to make specialty drugs, including biologics and biosimilars, is further stressing balance sheets.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more